Summary
Sera from 61 patients with systemic lupus erythematosus (SLE) were serially screened over a period of at least 2 years for IFN and anti-IFN antibodies. IFN concentrations were measured both with a cytopathic effect assay and a more sensitive radioimmunoassay. Of the patients 15% (9/61) had IFN in their serum at one or more occasions as measured in the bioassay (≥6 IU/ml); employing a RIA (≥1 IU/ml) 28% (17/61) of the patients studied were positive for IFN-α. Fifteen patients had a measurable interferonemia over 2–16 months; only two patients had detectable IFN in their serum at only one occasion. In five patients, hourly and daily variations of the IFN titer as measured by RIA were found to amount to less than 80%. The IFN activity found in these sera was characterized as IFN-α by means of acid stability, cross-reactivity on heterologous cells, trypsin sensitivity, and neutralization by homologous and heterologous antisera. IFN antibodies were quantified with a neutralization bioassay, an ELISA, and a radioimmunoassay. Of the 61 patients 5% (3) possessed high titers of anti-IFN antibodies which persisted over 2 years. The IFN-α antibody positive patients had an inactive form of the disease over years without visceral involvement but decreased serum complement levels (C4, C3, CH50) and repeated episodes of Quincke-like edema.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Branca AA, Baglioni C (1981) Evidence that types I and II interferons have different receptors. Nature 294:768–770
Stewart II WE (1981) VI. Interferon production. In: The IFN system. Springer, Berlin Heidelberg New York
Kirchner H, Zawatzky R, Engler H, Schirrmacher V, Becker H, von Wussow P (1979) Production of IFN in the mixed lymphocyte culture. II. IFN production is a T cell dependent function, independent of proliferation. Eur J Immunol 9:824–826
Stringfellow DA (1983) Nonpolynucleotide inducers of interferon. In: Came PE, Carter WA (eds) Handbook of experimental pharmacology, vol 71. Springer, Berlin Heidelberg New York
Skurkovich SV, Eremkina EI (1975) The probable role of IFN in allergy. Ann Allergy 35:356–360
Hooks JJ, Montsopoulos HM, Notkins AL (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301:5–8
Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J (1982) Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leucocyte interferon. Science 216:429–431
Ytterberg SR, Schnitzer TJ (1982) Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25:401–406
Wussow P von, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-α antibody titers during IFN therapy. Lancet II:635–636
Ho M, Enders JF (1959) An inhibitor of viral activity appearing in infected cell cultures. Proc Natl Acad Sci USA 45:385–389
Parry RP, Parry JV (1981) Interferon assay as a diagnostic test. Lancet I:506–507
Hooks JJ, Jordan WG, Cuppos T, Montsopoulos HM, Fauci AS, Notkins AL (1982) Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 25:396–400
Capou DJ, Shepard HM, Goeddel DV (1985) Two distinct families of human and bovine interferon-α genes are coordinately expressed and encode functional polypeptides. Mol Cell Biol 5:768–779
Spiegel J, Spicehandler JR, Jacobs SL, Oden EM (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alpha 2b interferon. Am J Med 80:223–228
Itri LM, Campion M, Dennice R, Palleroni A, Gutterman JU, Groopman J, Trowce PW (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving Roferon A by intramuscular injection. Cancer 59:668–674
Sergiescu D, Cerutti I, Ethymiou E, Kakan A, Chany C (1979) Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 31:48–51
Heremans H, Billian A, Colombatti, Hilgers J, Somer P de (1978) Interferon treatment of NZB mice; accelerated progression of autoimmune disease. Infect Immun 21:925–930
Adam C, Thoua Y, Ronco P, Verroust P, Tovey MG, Morel-Maroger L (1980) The effect of exogenous interferon: acceleration of autoimmune and renal disease in (NZB/W) F1 mice. Clin Exp Immunol 40:373–382
Rotem Z, Cox RA, Isaac A (1963) Inhibition of virus multiplication by foreign nucleic acid. Nature 197:564–566
Eyser E, Geodert J, Poon MC, Preble O (1983) Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia. N Engl J Med 304:583–586
Kennedy P, Narayan N, Ghotbi Z, Hopkins J, Gendleman H, Clements JE (1985) Persistent expression of I a antigen and viral genome in Visna-Maedi virus-induced inflammatory cells. Possible role of lentivirus-induced interferon. J Exp Med 162:1970–1982
Cohen AS, Reynolds WE, Franklin EC, Kulka JP, Ropes MW, Shulman LE, Wallace SL (1971) Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21:643–648
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
von Wussow, P., Jakschies, D., Hartung, K. et al. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 8, 225–230 (1988). https://doi.org/10.1007/BF00269199
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00269199